Compare Quest Diagnostics Inc (DGX) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs KLA Corp. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while KLA Corp. trades at $234.64 (market cap $300.93B). The key difference: KLA Corp. is far larger — about 13.2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | KLAC | |
|---|---|---|
Market Cap | $22.80B | $300.93B |
Sector | Health | Technology |
52-Week High | $216.02 | $301.71 |
52-Week Low | $166.42 | $84.39 |
Enterprise Value | $28.82B | $302.11B |
Dividend Yield | 1.67% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
KLA Corporation (KLAC) trades at $222.25, down 4.0% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock exhibits strong fundamentals with revenue growth to $12.16B in 2025 and net income of $4.06B, though valuation multiples remain elevated. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid in June 2026.
Outlook remains supported by AI-driven semiconductor equipment demand and consistent earnings beats, but rich valuation and competitive pressures pose risks. Analyst consensus is bullish with a $239.86 price target, suggesting potential upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
